Life Sciences Industry Extra: Mintz Levin’s Joel Papernik to Speak at BIO International Convention
5/29/2008
IPO Ultimate Survival Guide
Thursday, June 19, 2008
4:00 pm - 5:30 pm
San Diego Convention Center
Room 31 ABC
111 W. Harbor Drive
San Diego, Calif.
Topic Description
Despite the choppy markets, many companies are beginning to prepare for an eventual entry in the public markets. Unfortunately, few realize the tremendous preparation—often beginning a year in advance—required for a successful IPO. In this panel, a boutique as well as a global banker, a venture capitalist, a firm lawyer, and an in-house counsel will explain what you should expect during the IPO process, how to choose your IPO team, and how to avoid common mistakes. We’ll also hear from a panelist who has been on both sides of the table. A must for anyone with an eye on the next IPO window!
Objectives
- Provide practical guidance to early-stage life science companies on how and when to secure public funding.
- Provide an overview of key areas of preparation for an IPO, including valuation, compliance, documentation, board books, etc.
- Provide the perspective of entrepreneurs and early-stage investors, as well as large and small boutique investment banks, on the goals and strategies involved.
Panelist Biographies
Joel I. Papernik
Member, Corporate
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Joel is a Member in Mintz Levin’s New York office, where he practices in the Corporate and Securities groups. Joel has extensive experience counseling high-technology businesses and the individuals creating them. Joel frequently guides acquisitions, collaborations, and licensing transactions in the biotechnology field. He is a member of his firm’s Policy Committee, co-chair of the firm’s Mergers & Acquisitions practice, and is a member of its Opinions Committee. Joel has been selected for listing in the 2007 edition of The Best Lawyers in America, and in 2007 was named one of “New York Area’s Best Lawyers” in New York Magazine. Joel was also named a 2007 “New York Super Lawyer” in The New York Times. He currently serves on the Securities Law Committee of the NYSBA, the TriBar Opinion Committee, and the negotiated acquisitions committee of the ABA. He is currently a board member for the New York Biotechnology Association.
John Brooks
President and Managing Director
Medical Capital Group
John is president and managing director of Medical Capital Group, a healthcare merchant banking firm that provides investment banking, strategic advice, and growth and development capital to life science companies. He was a co-founder of Prism VentureWorks and played a key role in the firm’s development over the years. He currently sits on the boards of OptiScan Biomedical, Confirma, MedManage Systems, Uptake Medical, and the Joslin Diabetes Center. John was formerly general manager at Pfizer/Valleylab where he developed and executed a minimally invasive surgery strategy. At Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business. John has cofounded three life sciences companies: Songbird Hearing, Locus Pharmaceuticals, and Insulet (PODD). John holds an MS in Business and a BBA cum laude from the University of Massachusetts at Amherst. He is a Certified Public Accountant and a Certified Financial Planner.
Michelle Dipp, MD, PhD
Director of Corporate Development
Sirtris Pharmaceuticals
Michelle is the Senior Director of Corporate Development for Sirtris Pharmaceuticals, Inc. Prior to joining Sirtris, Michelle worked in healthcare private equity at The Wellcome Trust, London. She previously did post-doctoral research in the Department of Pharmacology and the Department of Cardiothoracic Surgery at John Radcliffe Hospital, Oxford, England. She has published several papers in peer-reviewed journals in the pulmonary field. Michelle holds an MD and a PhD in Pulmonary Physiology from the University of Oxford.
Jonathan Gertler, MD
Managing Director, Head of BioPharma Investment Banking
Leerink Swann and Company
Jonathan is responsible for all investment banking activities related to the biotechnology and specialty pharmaceutical sectors. Dr. Gertler holds a BA from Wesleyan University, an MD from Columbia University College of Physicians and Surgeons, and an MBA in Health Policy and Management from Boston University. He trained in general surgery at Yale University and in vascular surgery at Massachusetts General Hospital in Boston.
Joshua Muntner
Executive Director
Oppenheimer & Co.
Josh Muntner joined CIBC World Markets (now Oppenheimer) in March 2000. His experience includes over 40 completed transactions for biopharmaceutical companies, including public offerings, private financings, and financial advisory assignments. Previously, Josh worked as an investment banker for Prudential Vector Healthcare in New York. Josh received a BFA from Carnegie Mellon University and an MBA from the Anderson School at UCLA.
For more information please contact:
Joel I. Papernik
(212) 692-6774
JIPapernik@mintz.com
